Secukinumab (Anti-IL-17A antibody) and Fontolizumab (anti-IFN-γ antibody) are being tested in rheumatoid arthritis (RA) (NCT00281294) and psoriasis (NCT04711902, NCT04632927). Here, IFNG is linked to rheumatoid arthritis.